a.  Designs and requirements for studies on antihypertensive drugs
b.  Pharmacokinetics of antihypertensive drugs
c.  Pharmacodynamics of antihypertensive drugs
d.  Drug interactions
e.  Antihypertensive drug classes

   I. Historical notes
   II. Diuretics:

- Thiazides
- Loop diuretics
- Potassium sparing diuretics

   III. Sympatholitics:

- Central agents

   http://www.eshonline.org/education/archivio/lectures/clement.htm
   D.L. Clement (Ghent, Belgium, Centrally Acting Drugs

- Alfa-blockers
- Beta-blockers
- Alfa/Beta blockers

   IV. Calcium channel blockers:

- Dihydropiridines
- Phenylalkilamines

   V. Angiotensin converting enzyme inhibitors
   VI. Angiotensin receptor antagonists
   VII.   Vasopeptidase inhibitors
   VIII.  Endothelin antagonists

Topical Workshop 7:  Endothelins in Hypertension and Cardiovascular Disease; 14 June 2006
http://www.eshonline.org/education/congresses/2006/esh/14_giu_art7.asp

   IX. Other vasodilators
   X. Hybrids
   XI. Perspectives

http://www.eshonline.org/education/congresses/2006/esh/teaching_seminars.asp#javascript();
Thursday, June 15 Teaching Seminar 10; 2006
T. Unger, DE; Interventions of new mechanisms

f.   Therapeutic strategies

WEBCASTS: Plenary Session - Auditorium, 15 June 2006
New-onset diabetes and antihypertensive drugs; G. Mancia, IT
http://www.eshonline.org/education/congresses/2006/esh/15_giu_PS_AU.asp

  I.    Principles guiding choice of initial drug
 
  II.   Principles guiding drug combinations

Seminars 2001;
http://www.eshonline.org/education/archivio/lectures/zweiten.htm
P.A. van Zwieten (Amsterdam, The Netherlands); How to use Diuretics, Beta- blockers, Calcium Antagonists and Combination Therapy?

http://www.eshonline.org/education/newsletter.htm
Beneficial Combinations of Two or More Antihypertensive Agents; P. A. van    Zwieten, C. Farsang)
Newsletter no 18

  III.  Step-care approach
  IV.  Sequential monotherapy
  V.   Combination treatment as first choice
  VI.  Fixed combinations. Advantages/disadvantages
  VII. Preferential and compelling drug choices

http://www.eshonline.org/education/archivio/esh2003/teaching_seminars_2003.htm
16 June, 2004, D. van Zwieten, Controversies in anty_HT treatement.

  VIII. Treatment maintenance and duration
  IX.  Strategies for improving compliance to treatment

http://www.eshonline.org/education/congresses/esh_2005/teaching_seminars.asp
Monday, June 20, 2005
How to improve compliance to antihypertensive therapy Prof. X. Girerd

http://www.eshonline.org/education/newsletter.htm
Patient Compliance in the Treatment of Arterial Hypertension; (J.-M. Mallion, D.   Schmitt)
Newsletter no 8

  X.   Assessment of adverse effects

http://www.eshonline.org/education/newsletter.htm
Interactions between Antihypertensive Agents and Other Drugs; P. A. van Zwieten,    C. Farsang)
Newsletter no 18

  XI.  Associated antiaggregant and lipid lowering treatments

Teaching Session Wednesday, June 26
http://www.eshonline.org/education/archivio/esh2002/webcourse.htm;
INTERACTION BETWEEN ANTIHYPERTENSIVE AND OTHER DRUGS; van Zwieten P